Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1976 Jan;57(1):39–46. doi: 10.1172/JCI108266

Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.

N K Hollenberg, G H Williams, B Burger, I Ishikawa, D F Adams
PMCID: PMC436622  PMID: 1245602

Abstract

We have assessed the capacity of an analogue of angiotensin II (A II), 1-Sar, 8-Ala A II (P113) in normal man to stimulate and block responses to A II in four systems: blood pressure was monitored directly from an arterial catheter, and renal blood flow was measured with 133Xe and arterial renin and aldosterone concentrations by radioimmunoassay. The 31 normal subjects were in balance on a daily intake of 200 meg sodium and 100 meq potassium to suppress endogenous renin. P113 administered intravenously induced a dose-related renal blood flow reduction, with a threshold dose of 0.1 mug/kg/min. This dose also induced a small but significant increase in arterial blood pressure and plasma aldosterone as well as a reduction in plasma renin activity. In contrast to its effect on the renal vasculature, no tendency to a progressive response in the latter three parameters was noted as the P113 dose was increased 30-fold, to 3.0 mug/kg/min. P113 also reduced the clearance of para-aminohippurate, creatinine, sodium, and potassium, a pattern similar to that induced by A II. P113 at 0.1 mug/kg/min reduced significantly the blood pressure and renal vascular and aldosterone responses to graded doses of A II. Higher P113 doses totally obliterated all three responses to A II infused at 10 ng/kg/min, a dose that provides arterial A II concentrations in the range found in angiotensin-mediated hypertension. When A II was infused first, to induce a pressor, renal vascular, and aldosterone response, P113 induced a dose-related reversal of the response in each system. In conclusion, P113 is a partial agonist in normal man, inducing an angiotensin-like response in settings in which endogenous A II is not playing a tonic role, and displaying dominant antagonist activity in settings in which A II is active. Moreover, the studies suggest that the receptors mediating the responses to A II are different in the renal vasculature and other systemic vascular beds. The adrenal receptor must also differ. This agent should be useful in dissecting the role of A II in diseases characterized by hypertension or abnormalities of renal and adrenal function.

Full text

PDF
39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brunner H. R., Gavras H., Laragh J. H. Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet. 1973 Nov 10;2(7837):1045–1048. doi: 10.1016/s0140-6736(73)92657-3. [DOI] [PubMed] [Google Scholar]
  2. Brunner H. R., Kirshman J. D., Sealey J. E., Laragh J. H. Hypertension of renal origin: evidence for two different mechanisms. Science. 1971 Dec 24;174(4016):1344–1346. doi: 10.1126/science.174.4016.1344. [DOI] [PubMed] [Google Scholar]
  3. Emanuel R. L., Cain J. P., Williams G. H. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med. 1973 Apr;81(4):632–640. [PubMed] [Google Scholar]
  4. Freeman R. H., Davis J. O., Vitale S. J., Johnson J. A. Intrarenal role of angiotensin II. Homeostatic regulation of renal blood flow in the dog. Circ Res. 1973 Jun;32(6):692–698. doi: 10.1161/01.res.32.6.692. [DOI] [PubMed] [Google Scholar]
  5. Gagnon D., Park W. K., Regoli D. Specific antagonists for the myotropic action of angiotensin II and angiotensin I on the isolated rat colon. Br J Pharmacol. 1971 Oct;43(2):409–410. [PMC free article] [PubMed] [Google Scholar]
  6. Hall M. M., Khosla M. C., Khairallah P. A., Bumpus F. M. Angiotensin analogs: the influence of sarcosine substituted in position 1. J Pharmacol Exp Ther. 1974 Jan;188(1):222–228. [PubMed] [Google Scholar]
  7. Hollenberg N. K., Adams D. F., Solomon H. S., Rashid A., Abrams H. L., Merrill J. P. Senescence and the renal vasculature in normal man. Circ Res. 1974 Mar;34(3):309–316. doi: 10.1161/01.res.34.3.309. [DOI] [PubMed] [Google Scholar]
  8. Hollenberg N. K., Chenitz W. R., Adams D. F., Williams G. H. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Invest. 1974 Jul;54(1):34–42. doi: 10.1172/JCI107748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Khairallah P. A., Toth A., Bumpus F. M. Analogs of angiotensin II. II. Mechanism of receptor interaction. J Med Chem. 1970 Mar;13(2):181–184. doi: 10.1021/jm00296a003. [DOI] [PubMed] [Google Scholar]
  10. Lachance J. G., Brunette M. G., Carrière S. Inhibition of intrarenal angiotensin II effect by (1-Sar-8-Gly-)-AII. Rev Can Biol. 1973 Sep;32(3):219–228. [PubMed] [Google Scholar]
  11. Marshall G. R., Vine W., Needlemann P. A specific competitive inhibitor of angiotensin II. Proc Natl Acad Sci U S A. 1970 Nov;67(3):1624–1630. doi: 10.1073/pnas.67.3.1624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mimran A., Guiod L., Hollenberg N. K. The role of angiotensin in the cardiovascular and renal response to salt restriction. Kidney Int. 1974 May;5(5):348–355. doi: 10.1038/ki.1974.50. [DOI] [PubMed] [Google Scholar]
  13. Mimran A., Hinrichs K. J., Hollenberg N. K. Characterization of smooth muscle receptors for angiotensin: studies with an antagonist. Am J Physiol. 1974 Jan;226(1):185–190. doi: 10.1152/ajplegacy.1974.226.1.185. [DOI] [PubMed] [Google Scholar]
  14. Needleman P., Kauffman A. H., Douglas J. R., Jr, Johnson E. M., Jr, Marshall G. R. Specific stimulation and inhibition of renal prostaglandin release by angiotensin analogs. Am J Physiol. 1973 Jun;224(6):1415–1419. doi: 10.1152/ajplegacy.1973.224.6.1415. [DOI] [PubMed] [Google Scholar]
  15. Ogihara T., Yamamoto T., Kumahara Y. Clinical applications of synthetic angiotensin II analogue. Jpn Circ J. 1974 Nov;38(11):997–1003. doi: 10.1253/jcj.38.997. [DOI] [PubMed] [Google Scholar]
  16. Pals D. T., Masucci F. D., Denning G. S., Jr, Sipos F., Fessler D. C. Role of the pressor action of angiotensin II in experimental hypertension. Circ Res. 1971 Dec;29(6):673–681. doi: 10.1161/01.res.29.6.673. [DOI] [PubMed] [Google Scholar]
  17. Park W. K., Regoli D., Rioux F. Characterization of angiotensin receptors in vascular and intestinal smooth muscles. Br J Pharmacol. 1973 Jun;48(2):288–301. doi: 10.1111/j.1476-5381.1973.tb06915.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Peach M. J. Adrenal medullary stimulation induced by angiotensin I, angiotensin II, and analogues. Circ Res. 1971 May;28(5 Suppl):107–117. doi: 10.1161/01.res.28.5.ii-107. [DOI] [PubMed] [Google Scholar]
  19. Regoli D., Park W. K., Rioux F., Chan C. S. Antagonists of angiotensin. Substitution of an aliphatic chain to phenyl ring in position 8. Rev Can Biol. 1971 Dec;30(4):319–329. [PubMed] [Google Scholar]
  20. Regoli D., Rioux F., Park W. K., Choi C. Role of the N-terminal amino acid for the biological activities of angiotensin and inhibitory analogues. Can J Physiol Pharmacol. 1974 Feb;52(1):39–49. doi: 10.1139/y74-006. [DOI] [PubMed] [Google Scholar]
  21. STEPHENSON R. P. A modification of receptor theory. Br J Pharmacol Chemother. 1956 Dec;11(4):379–393. doi: 10.1111/j.1476-5381.1956.tb00006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smith H. W., Finkelstein N., Aliminosa L., Crawford B., Graber M. THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest. 1945 May;24(3):388–404. doi: 10.1172/JCI101618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Steele J. M., Jr, Lowenstein J. Differential effects of an angiotensin II analogue on pressor and adrenal receptors in the rabbit. Circ Res. 1974 Oct;35(4):592–600. doi: 10.1161/01.res.35.4.592. [DOI] [PubMed] [Google Scholar]
  24. Streeten D. H., Anderson G. H., Freiberg J. M., Dalakos T. G. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. N Engl J Med. 1975 Mar 27;292(13):657–662. doi: 10.1056/NEJM197503272921301. [DOI] [PubMed] [Google Scholar]
  25. Underwood R. H., Williams G. H. The simultaneous measurement of aldosterone, cortisol, and corticosterone in human peripheral plasma by displacement analysis. J Lab Clin Med. 1972 May;79(5):848–862. [PubMed] [Google Scholar]
  26. Williams G. H., McDonnell L. M., Raux M. C., Hollenberg N. K. Evidence for different angiotensin II receptors in rat adrenal glomerulosa and rabbit vascular smooth muscle cells. Studies with competitive antagonists. Circ Res. 1974 Mar;34(3):384–390. doi: 10.1161/01.res.34.3.384. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES